Ebselen

Phase 3Small molecule

SSound Pharmaceuticals, Incorporated

Ebselen is one of 93 small molecule programs targeting Meniere disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Meniere DiseaseCompleted

Hearing LossRecruiting

Diabetes MellitusActive, not recruiting

COVID-19Active, not recruiting

Meniere DiseasePhase 3

Completed

Hearing LossPhase 2

Recruiting

Diabetes MellitusPhase 2/Phase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Ebselen

SSound Pharmaceuticals, Incorporated

Phase 3

2 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Singulair

AstraZeneca

Preclinical

1 5

Calciferol

Alnylam Pharmaceuticals

Activella

Aprotinin

1 8

Selenium

SSWOG Cancer Research Network

Preclinical

1 9

Antithrombin-III

Octapharma

Preclinical

1 10

DAS181

AAnsun Biopharma, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Meniere Disease

NCT06859788

Phase 2Recruiting

Hearing Loss

NCT06340633

Clinical

Trials by Indication[1]

COVID-192 trials

SPI-1005 Treatment in Moderate COVID-19 Patients

Unknown status·SSound Pharmaceuticals, Incorporated·Phase 2·NCT04484025·60 enrolled

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients

Completed·SSound Pharmaceuticals, Incorporated·Phase 2·NCT04483973·25 enrolled

Meniere disease2 trials

Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease

Active, not recruiting·SSound Pharmaceuticals, Incorporated·Phase 3·NCT06859788·200 enrolled

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005

Completed·SSound Pharmaceuticals, Incorporated·Phase 3·NCT04677972·254 enrolled

Treatment1 trial

Ebselen as an add-on Treatment in Hypo/Mania

Completed·UUniversity of Oxford·Phase 2·NCT03013400·60 enrolled

Diabetes Mellitus1 trial

Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus

Completed·—·Phase 2/3·NCT00762671·60 enrolled

Treatment Resistant Depression1 trial

IMPase in Treatment-resistant Depression

Unknown status·UUniversity of Oxford·Phase 1·NCT05117710·50 enrolled

1 more indication

Hearing Loss1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Adults Receiving a Cochlear Implant

Recruiting·SSound Pharmaceuticals, Incorporated·Phase 2·NCT06340633·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Ebselen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ebselen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ebselen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sound Pharmaceuticals, Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSound Pharmaceuticals, Incorporated

Ebselen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

COVID-192 trials

Meniere disease2 trials

Treatment1 trial

Diabetes Mellitus1 trial

Treatment Resistant Depression1 trial

Hearing Loss1 trial

References

Drug Info

Quick Facts

Related News